Item 1.01 Entry into a Material Definitive Agreement.
On
Under the Sales Agreement, the Company will set the parameters for the sale of
the Shares, including the number of Shares to be issued, the time period during
which sales are requested to be made, limitations on the number of Shares that
may be sold in any one trading day and any minimum price below which sales may
not be made. Subject to the terms and conditions of the Sales Agreement,
The Company is not obligated to make any sales of Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (i) the sale of all Common Stock subject to the Sales Agreement or (ii) termination of the Sales Agreement in accordance with its terms.
The representations and warranties contained in the Sales Agreement were made
only for purposes of the transactions contemplated by the Sales Agreement as of
specific dates and may have been qualified by certain disclosures between the
parties and a contractual standard of materiality different from those generally
applicable under securities laws, among other limitations. The representations
and warranties were made for purposes of allocating contractual risk between the
parties to the Sales Agreement and should not be relied upon as a disclosure of
factual information relating to the Company,
The foregoing description of the material terms of the Sales Agreement is qualified in its entirety by reference to the full agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The Shares will be sold pursuant to the Registration Statement, and offerings of the Shares will be made only by means of the Prospectus Supplement. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of any offer to buy the securities discussed herein, nor shall there be any offer, solicitation or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
A legal opinion relating to the Shares is included as Exhibit 5.1 to this Current Report on Form 8-K.
Item 8.01 Other Events.
On
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 1.1 Sales Agreement, dated as ofSeptember 30, 2021 , by and betweenEloxx Pharmaceuticals, Inc. andSVB Leerink, LLC . 5.1 Opinion ofLatham & Watkins LLP . 23.1 Consent ofLatham & Watkins LLP (included in Exhibit 5.1 hereto). 23.2 Consent ofMoody, Famiglietti & Andronico, LLP , Independent Registered Public Accounting Firm
© Edgar Online, source